• Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans

Subscribe to Updates

Get the latest finance news and updates directly to your inbox.

Top News

Tony Robbins: 401(K) Fees Could Rob You of 10 Years of Retirement Income

June 22, 2025

11 Cheap Business Ideas You Can Start for Less Than $1,000

June 22, 2025

Is Your Savings Account a Crutch for Bad Life Choices?

June 21, 2025
Facebook Twitter Instagram
Trending
  • Tony Robbins: 401(K) Fees Could Rob You of 10 Years of Retirement Income
  • 11 Cheap Business Ideas You Can Start for Less Than $1,000
  • Is Your Savings Account a Crutch for Bad Life Choices?
  • The Best Defense Against Uncertainty Isn’t a Single Strategy — It’s a Mindset
  • Tackle Decision Fatigue With This CEO-Worthy AI Tool
  • How to Turn Bad Reviews Into Great News For Your Business
  • This $180 Chromebook Offers Flexibility and Performance for On-the-Go Entrepreneurs
  • 5 Things To Ask Aging Parents About Emergency Evacuations
Sunday, June 22
Facebook Twitter Instagram
FintechoPro
Subscribe For Alerts
  • Home
  • News
  • Personal Finance
    • Savings
    • Banking
    • Mortgage
    • Retirement
    • Taxes
    • Wealth
  • Make Money
  • Budgeting
  • Burrow
  • Investing
  • Credit Cards
  • Loans
FintechoPro
Home » Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
News

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%

News RoomBy News RoomAugust 9, 20230 Views0
Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email Tumblr Telegram

Shares of Danish drugmaker Novo Nordisk soared Tuesday, after late-stage trial data showed that its obesity drug Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo.

The results of the closely watched “SELECT” trial, which exceeded expectations, were seen as a major boost for the company’s hopes of moving beyond Wegovy’s image as a “vanity drug.”

Shares of Novo Nordisk ended the session up over 17%.

The double-blind trial began almost five years ago and involved more than 17,600 adults with established cardiovascular disease who were overweight or suffered from obesity, but had no prior history of diabetes.

The headline results show that the weekly injection of semaglutide 2.4 mg achieved its primary objection of reducing the risk of cardiovascular events, such as heart attacks or strokes, by 20% compared with a placebo. Wegovy contains 2.4 mg of semaglutide.

CNBC Health & Science

Read CNBC’s latest health coverage:

Investors and analysts had told Reuters that a risk reduction of between 15% and 17% would be interpreted as a positive result for the blockbuster weight loss drug.

Martin Holst Lange, executive vice president for development at Novo Nordisk, said that the results showed that the company’s obesity drug “has the potential to change how obesity is regarded and treated.”

“People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death,” Holst Lange said in a statement.

“Therefore, we are very excited about the results from SELECT showing that semaglutide 2.4 mg reduces the risk of cardiovascular events.”

The company said it expects to file for regulatory approvals of a label indication expansion for Wegovy in the U.S. and European Union this year.

Emily Field, head of European pharmaceuticals equity research at Barclays, told CNBC last month that the results of Novo Nordisk’s SELECT trial amounted to an important litmus test for the health industry.

In the event that the drug was found to have wider-reaching applications, including cardiovascular benefits, Field said that it was more likely that it could be adopted under mainstream health-care policies.

Public health services “don’t want to pay for it, if it won’t tackle underlying health conditions,” she said.

The detailed results from the SELECT trial will be presented at a scientific conference later in the year, Novo Nordisk said, without fully disclosing the timeline.

— CNBC’s Karen Gilchrist contributed to this report.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

RSS Feed Generator, Create RSS feeds from URL

News November 22, 2024

X CEO Linda Yaccarino addresses Musk’s ‘go f—- yourself’ comment to advertisers

News November 30, 2023

67-year-old who left the U.S. for Mexico: I’m happily retired—but I ‘really regret’ doing these 3 things in my 20s

News November 30, 2023

U.S. GDP grew at a 5.2% rate in the third quarter, even stronger than first indicated

News November 29, 2023

Americans are ‘doom spending’ — here’s why that’s a problem

News November 29, 2023

Jim Cramer’s top 10 things to watch in the stock market Tuesday

News November 28, 2023
Add A Comment

Leave A Reply Cancel Reply

Demo
Top News

11 Cheap Business Ideas You Can Start for Less Than $1,000

June 22, 20250 Views

Is Your Savings Account a Crutch for Bad Life Choices?

June 21, 20250 Views

The Best Defense Against Uncertainty Isn’t a Single Strategy — It’s a Mindset

June 21, 20250 Views

Tackle Decision Fatigue With This CEO-Worthy AI Tool

June 21, 20250 Views
Don't Miss

How to Turn Bad Reviews Into Great News For Your Business

By News RoomJune 21, 2025

Entrepreneur No matter how robust your brand’s customer service is, you can’t avoid negative feedback…

This $180 Chromebook Offers Flexibility and Performance for On-the-Go Entrepreneurs

June 21, 2025

5 Things To Ask Aging Parents About Emergency Evacuations

June 21, 2025

A 16-Billion Password Leak Just Hit. Are You at Risk?

June 21, 2025
Facebook Twitter Instagram Pinterest Dribbble
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact
© 2025 FintechoPro. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.